Alzamend Neuro Inc
Research Alzamend Neuro Inc (ALZN) on Bullrun: market cap USD 6.81M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALZN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 6.81M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 2.87M
- Free cash flow-USD 2.80M
Valuation Snapshot
latest market cap is USD 6.81M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 4.51M | -USD 5.86M | n/a | -11.32 | USD 3.95M | n/a | USD 3.97M |
| FY2024 | USD 0 | -USD 9.95M | -USD 8.00M | n/a | -132.33 | USD 376.05K | USD 300.71K | -USD 2.59M |
| FY2023 | n/a | -USD 14.88M | n/a | n/a | -22.89 | USD 5.14M | n/a | USD 3.05M |
| FY2022 | n/a | -USD 12.36M | n/a | n/a | -0.14 | USD 14.06M | n/a | USD 13.35M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 6.81M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 6.92M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 6.30M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 6.34M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 54.46M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 168.78M | n/a | n/a | n/a |
About Alzamend Neuro Inc
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Alzamend Neuro Inc's market cap?
Alzamend Neuro Inc's market capitalization is USD 6.81M.
What does Alzamend Neuro Inc do?
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.